FR12C0034I2 - Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii - Google Patents

Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii

Info

Publication number: FR12C0034I2
Authority: FR; France
Prior art keywords: receptor antagonists; benzimidazole derivatives; benzimidazole; derivatives; antagonists
Prior art date: 2004-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR12C0034C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Lim

Original Assignee

Takeda Pharmaceutical Co Lim

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2012-05-11

Publication date

2013-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-11 Application filed by Takeda Pharmaceutical Co Lim filed Critical Takeda Pharmaceutical Co Lim

2012-06-15 Publication of FR12C0034I1 publication Critical patent/FR12C0034I1/fr

2013-01-11 Application granted granted Critical

2013-01-11 Publication of FR12C0034I2 publication Critical patent/FR12C0034I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pyrrole Compounds (AREA)

FR12C0034C 2004-02-25 2012-05-11 Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii Active FR12C0034I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004048928		2004-02-25
US11/031,057 US7157584B2 (en)	2004-02-25	2005-01-07	Benzimidazole derivative and use thereof
PCT/JP2005/003422 WO2005080384A2 (fr)	2004-02-25	2005-02-23	Dérivé du benzimidazole et ses utilisations

Publications (2)

Publication Number	Publication Date
FR12C0034I1 FR12C0034I1 (fr)	2012-06-15
FR12C0034I2 true FR12C0034I2 (fr)	2013-01-11

Family

ID=34858222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR12C0034C Active FR12C0034I2 (fr)	2004-02-25	2012-05-11	Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii

Country Status (35)

Country	Link
US (3)	US7157584B2 (fr)
EP (3)	EP2119715B1 (fr)
JP (2)	JP4256852B2 (fr)
KR (1)	KR101080029B1 (fr)
CN (2)	CN100503605C (fr)
AR (2)	AR047972A1 (fr)
AT (2)	ATE440095T1 (fr)
AU (1)	AU2005214271B8 (fr)
BE (1)	BE2012C025I2 (fr)
BR (2)	BR122012009489B8 (fr)
CA (1)	CA2557538C (fr)
CY (5)	CY1107008T1 (fr)
DE (3)	DE602005002030T2 (fr)
DK (3)	DK2119715T3 (fr)
ES (3)	ES2331209T3 (fr)
FR (1)	FR12C0034I2 (fr)
HK (2)	HK1098472A1 (fr)
HR (3)	HRP20070510T3 (fr)
HU (1)	HUS1200008I1 (fr)
IL (1)	IL177533A (fr)
LU (1)	LU91962I2 (fr)
MA (1)	MA28478B1 (fr)
ME (2)	ME01089B (fr)
MY (1)	MY142807A (fr)
NL (1)	NL300802I2 (fr)
NO (2)	NO332344B1 (fr)
NZ (1)	NZ549755A (fr)
PL (3)	PL1857457T3 (fr)
PT (3)	PT2119715E (fr)
RS (3)	RS51137B (fr)
RU (2)	RU2501798C2 (fr)
SI (3)	SI1857457T1 (fr)
TW (1)	TWI336702B (fr)
WO (1)	WO2005080384A2 (fr)
ZA (1)	ZA200607241B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
CN101087619B (zh)	2004-12-24	2012-12-05	西芬克斯医药有限公司	治疗或预防的方法
JP4465469B2 (ja) *	2005-02-21	2010-05-19	国立大学法人佐賀大学	循環器病マーカーとしてのインターロイキン１３
MY146254A (en) *	2005-03-30	2012-07-31	Takeda Pharmaceutical	Benzimidazole derivative and use thereof
WO2007097452A1 (fr) *	2006-02-27	2007-08-30	Takeda Pharmaceutical Company Limited	Emballage-coque à usage médical
WO2007097451A1 (fr)	2006-02-27	2007-08-30	Takeda Pharmaceutical Company Limited	Emballage pharmaceutique
JP5230595B2 (ja) *	2006-03-20	2013-07-10	スピニフェクスファーマシューティカルズピーティーワイリミテッド	炎症性疼痛の治療または予防の方法
JP5340925B2 (ja) *	2006-09-25	2013-11-13	武田薬品工業株式会社	医薬パッケージ
JP5283632B2 (ja) *	2007-03-28	2013-09-04	武田薬品工業株式会社	ベンズイミダゾール−７−カルボキシレート誘導体およびｐＨ調整剤を含有する固形医薬組成物
JP2009062296A (ja) *	2007-09-05	2009-03-26	Fujifilm Corp	カルボン酸エステル化合物の製造方法
ES2510866T3 (es) *	2008-03-13	2014-10-21	Daiichi Sankyo Company, Limited	Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
EP2310385B1 (fr) *	2008-07-31	2017-06-07	Takeda Pharmaceutical Company Limited	Composition pharmaceutique solide
TW201014850A (en) *	2008-09-25	2010-04-16	Takeda Pharmaceutical	Solid pharmaceutical composition
EP2348857B1 (fr) *	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
WO2010075347A2 (fr)	2008-12-23	2010-07-01	Takeda Pharmaceutical Company Limited	Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
UY33380A (es)	2010-05-11	2011-12-01	Janssen Pharmaceutica Nv	Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
WO2012090043A1 (fr) *	2010-12-29	2012-07-05	Jubilant Life Sciences Limited	Nouvelles formes à l'état solide d'azilsartan médoxomil et leur procédé de préparation
CN102603723B (zh)	2011-01-20	2014-10-08	江苏豪森医药集团有限公司	阿齐沙坦有机胺盐及其制备方法和用途
WO2012107814A1 (fr)	2011-02-08	2012-08-16	Jubilant Life Sciences Limited	Procédé amélioré pour la préparation d'azilsartan médoxomil
CN102138899B (zh) *	2011-03-18	2013-08-21	海南本创医药科技有限公司	阿齐沙坦酯脂质体固体制剂
ES2586846T3 (es)	2011-04-13	2016-10-19	Janssen Pharmaceutica, N.V.	Proceso de preparación de compuestos útiles como inhibidores de SGLT2
CN102827153B (zh) *	2011-06-14	2016-10-05	江苏豪森药业集团有限公司	阿齐沙坦的晶型及其制备方法
CN102351853B (zh) *	2011-08-29	2014-03-12	石药集团欧意药业有限公司	一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042066A1 (fr) *	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Procédé de préparation d'azilsartan médoxomil
WO2013042067A1 (fr)	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Procédé de préparation d'un sel de potassium de l'azilsartan médoxomil
AP2014007766A0 (en)	2011-12-15	2014-07-31	Takeda Pharmaceuticals Usa Inc	Combination os azilsartan and chlorthlidone for treating hypertension black patients
WO2013088384A2 (fr)	2011-12-15	2013-06-20	Jubilant Life Sciences Limited	Formes à l'état solide d'azilsartan et d'azilsartan médoxomil monopotassique et leur procédé de préparation
WO2013104342A1 (fr) *	2012-01-14	2013-07-18	Sunshine Lake Pharma Co., Ltd.	Formes cristallines de l'azilsartan médoxomil potassique et préparation et utilisations de celles-ci
EP2814826A1 (fr) *	2012-02-02	2014-12-24	Ranbaxy Laboratories Limited	Procédé de préparation d'azilsartan médoxomil ou de ses sels pharmaceutiquement acceptables
WO2013124748A1 (fr) *	2012-02-20	2013-08-29	Alembic Pharmaceuticals Limited	Nouveaux polymorphes d'azilsartan médoxomil potassique
CZ2012274A3 (cs) *	2012-04-19	2013-10-30	Zentiva, K.S.	Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (fr) *	2012-06-11	2013-12-19	Msn Laboratories Limited	Procédé de préparation de 2-éthoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphényl-4-yl]méthyl}-lh-benzimidazole-7-carboxylate de (5-méthyl-2-oxo-l,3-dioxol-4-yl)méthyle et de ses sels
CA2884248A1 (fr) *	2012-07-09	2014-01-16	Hetero Research Foundation	Nouveaux polymorphes d'azilsartan
WO2014020381A1 (fr) *	2012-08-01	2014-02-06	Alembic Pharmaceuticals Limited	Forme cristalline inédite d'azilsartan médoxomil potassique
EP2925753A4 (fr) *	2012-08-27	2017-02-15	Hetero Research Foundation	Nouveaux polymorphes de l'azilsartan médoxomil
CZ305318B6 (cs) *	2012-09-26	2015-07-29	Zentiva, K.S.	Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
WO2014049512A2 (fr)	2012-09-26	2014-04-03	Lupin Limited	Nouveau procédé de préparation d'azilsartan médoxomil
CN103709154B (zh) *	2012-09-28	2016-06-15	武汉朗来科技发展有限公司	苯并咪唑衍生物及其制备方法和医药用途
AU2013329253B2 (en) *	2012-10-09	2017-02-23	Avery Dennison Corporation	Adhesives and related methods
CN103910720A (zh) *	2013-01-07	2014-07-09	广东东阳光药业有限公司	阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) *	2013-02-04	2018-09-25	武汉朗来科技发展有限公司	苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) *	2013-03-19	2018-02-21	トーアエイヨー株式会社	急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535004C1 (ru) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Способ лечения грыж межпозвонковых дисков у собак
RU2535005C1 (ru) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Способ лечения грыж межпозвонковых дисков у собак
CN104812752B (zh) *	2013-10-12	2016-09-28	杭州领业医药科技有限公司	阿齐沙坦酯的晶型及其制备方法
CN105949183B (zh) *	2013-10-12	2019-02-22	杭州领业医药科技有限公司	阿齐沙坦酯的晶型及其制备方法
CN104774197B (zh) *	2014-01-09	2017-11-17	武汉朗来科技发展有限公司	一种苯并咪唑衍生物的制备方法
CN104774196B (zh) *	2014-01-09	2017-11-10	武汉朗来科技发展有限公司	一种苯并咪唑衍生物的制备方法
CN105079815A (zh) *	2014-04-30	2015-11-25	广东东阳光药业有限公司	一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) *	2014-06-24	2014-09-03	浙江天宇药业股份有限公司	阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs)	2014-10-15	2016-04-27	Zentiva, K.S.	Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) *	2014-11-21	2016-06-01	重庆朗天制药有限公司	一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) *	2014-12-16	2016-07-13	重庆朗天制药有限公司	一种阿齐沙坦酯钾盐的新制备方法
WO2016145622A1 (fr)	2015-03-18	2016-09-22	武汉朗来科技发展有限公司	Dérivés de benzimidazole, leur procédé de préparation et leur utilisation médicinale
CN106032378B (zh) *	2015-03-20	2019-10-25	武汉启瑞药业有限公司	新型arb化合物及其用途
CN104803998B (zh) *	2015-03-26	2017-08-25	晋江市托美汀生物科技有限公司	一种降低杂质含量的方法
US20200179369A1 (en) *	2015-07-29	2020-06-11	Takeda Gmbh	Treatment of diabetic nephropathy
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) *	2016-11-30	2021-04-07	株式会社トクヤマ	アジルサルタンの製造方法
WO2017131218A1 (fr) *	2016-01-28	2017-08-03	株式会社トクヤマ	Azilsartan et son procédé de production
CN105628824B (zh) *	2016-03-06	2017-10-17	江苏正大清江制药有限公司	一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) *	2016-05-20	2020-10-23	武汉朗来科技发展有限公司	化合物及其制备方法、组合物和应用
CN105770876B (zh) *	2016-05-30	2019-09-10	广东天普生化医药股份有限公司	乌司他丁在制备治疗慢性前列腺炎药物中的用途
EP3461822B1 (fr) *	2016-07-11	2022-11-02	Wuhan LL Science And Technology Development Co., Ltd.	Forme cristalline de composé chimique, son procédé de préparation, sa composition et son application
RU2623082C1 (ru) *	2016-07-11	2017-06-21	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ коррекции артериальной ригидности у больных ревматоидным артритом
RU2634272C1 (ru) *	2016-08-10	2017-10-24	Закрытое акционерное общество "Санкт-Петербургский институт фармации"	Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) *	2016-08-30	2016-11-09	佛山市弘泰药物研发有限公司	一种阿齐沙坦酯钾盐分散片的制备方法
WO2018064945A1 (fr) *	2016-10-08	2018-04-12	武汉朗来科技发展有限公司	Composition pharmaceutique
IN201721047406A (fr)	2017-12-30	2020-06-19	Lupin Limited
CN110237072B (zh) *	2018-03-09	2022-03-25	武汉朗来科技发展有限公司	药物组合物的制备方法
CN110237071B (zh) *	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
EP3807892A1 (fr) *	2018-06-14	2021-04-21	AstraZeneca UK Limited	Méthodes de diminution de la tension artérielle avec une composition pharmaceutique de blocage de canal calcique de type dihydropyridine
WO2019241590A1 (fr)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Procédés de traitement de l'hypertension au moyen d'une composition pharmaceutique de blocage du récepteur de l'angiotensine ii
WO2020101450A1 (fr)	2018-11-16	2020-05-22	엠에프씨 주식회사	Composés dérivés d'azilsartan, leurs intermédiaires, leur procédé de préparation et composition pharmaceutique les comprenant
EP3925957A4 (fr) *	2019-02-15	2022-11-02	Tohoku University	Dérivé de 1, 3-dioxolane
KR102220011B1 (ko)	2020-05-15	2021-02-25	대봉엘에스 주식회사	친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) *	2021-11-03	2023-06-02	瑞孚信江苏药业股份有限公司	一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
AU2022428746A1 (en)	2021-12-28	2024-04-04	Alchemedicine, Inc.	Compound, angiotensin II type 1 receptor antagonist and pharmaceutical composition
KR20240039252A (ko)	2022-09-19	2024-03-26	대봉엘에스 주식회사	안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물
WO2024109927A1 (fr) *	2022-11-24	2024-05-30	上海云晟研新生物科技有限公司	Composition pharmaceutique comprenant du potassium d'azilsartan médoxomil et un bloqueur de canal calcique, son procédé de préparation et son utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62290071A (ja)	1986-06-09	1987-12-16	Matsushita Electric Ind Co Ltd	有機電解質二次電池
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2061607C (fr)	1991-02-21	1999-01-19	Hiroaki Yanagisawa	Derives 1-biphenylimidazole, leur preparation et leur utilisation therapeutique
US5616599A (en) *	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) *	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) *	1991-10-23	1998-08-20	Эйсаи Ко., Лтд.	Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) *	1992-08-06	1994-05-10	E. I. Du Pont De Nemours And Company	Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (ja) *	1993-02-26	1998-08-20	松森　　昭	ウイルス性疾患の予防または治療剤
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) *	1995-04-03	1997-03-11	Bristol-Myers Squibb Company	Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
IL153633A0 (en)	2000-07-13	2003-07-06	Takeda Chemical Insustries Ltd	Lipid-rich plaque inhibitors
AU2002349673A1 (en) *	2001-12-03	2003-06-17	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents
CN1615305A (zh)	2002-01-11	2005-05-11	武田药品工业株式会社	香豆素衍生物、生产它们的方法及其用途
US20070004736A1 (en)	2002-11-22	2007-01-04	Keiji Kubo	Imidazole derivative, process for producing the same, and use
US6972258B2 (en) *	2003-08-04	2005-12-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Method for selectively controlling damascene CD bias
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
JP4364171B2 (ja)	2005-07-15	2009-11-11	本田技研工業株式会社	自動車用ドアチェッカ
UA58542U (ru) *	2010-12-16	2011-04-11	Леонид Борисович Борейко	Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

2005
- 2005-01-07 US US11/031,057 patent/US7157584B2/en active Active
- 2005-02-23 ES ES07075609T patent/ES2331209T3/es not_active Expired - Lifetime
- 2005-02-23 CA CA2557538A patent/CA2557538C/fr not_active Expired - Lifetime
- 2005-02-23 EP EP08075903A patent/EP2119715B1/fr not_active Expired - Lifetime
- 2005-02-23 EP EP05719737A patent/EP1718641B1/fr not_active Expired - Lifetime
- 2005-02-23 RS RSP-2009/0484A patent/RS51137B/sr unknown
- 2005-02-23 DK DK08075903.8T patent/DK2119715T3/da active
- 2005-02-23 WO PCT/JP2005/003422 patent/WO2005080384A2/fr active Application Filing
- 2005-02-23 PT PT08075903T patent/PT2119715E/pt unknown
- 2005-02-23 RU RU2009115498/04A patent/RU2501798C2/ru active Protection Beyond IP Right Term
- 2005-02-23 AR ARP050100653A patent/AR047972A1/es active IP Right Grant
- 2005-02-23 KR KR1020067016710A patent/KR101080029B1/ko active Protection Beyond IP Right Term
- 2005-02-23 RU RU2006133898/04A patent/RU2369608C2/ru active Protection Beyond IP Right Term
- 2005-02-23 CN CNB2005800130733A patent/CN100503605C/zh not_active Expired - Lifetime
- 2005-02-23 MY MYPI20050690A patent/MY142807A/en unknown
- 2005-02-23 PT PT07075609T patent/PT1857457E/pt unknown
- 2005-02-23 PL PL07075609T patent/PL1857457T3/pl unknown
- 2005-02-23 AU AU2005214271A patent/AU2005214271B8/en active Active
- 2005-02-23 DK DK07075609T patent/DK1857457T3/da active
- 2005-02-23 NZ NZ549755A patent/NZ549755A/en unknown
- 2005-02-23 SI SI200530822T patent/SI1857457T1/sl unknown
- 2005-02-23 ME MEP-2009-323A patent/ME01089B/me unknown
- 2005-02-23 RS RS20120362A patent/RS52376B/en unknown
- 2005-02-23 RS RSP-2007/0448A patent/RS50537B/sr unknown
- 2005-02-23 AT AT07075609T patent/ATE440095T1/de active
- 2005-02-23 AT AT05719737T patent/ATE370136T1/de active
- 2005-02-23 PL PL05719737T patent/PL1718641T3/pl unknown
- 2005-02-23 DK DK05719737T patent/DK1718641T3/da active
- 2005-02-23 EP EP07075609A patent/EP1857457B1/fr not_active Expired - Lifetime
- 2005-02-23 ES ES08075903T patent/ES2388945T3/es not_active Expired - Lifetime
- 2005-02-23 PT PT05719737T patent/PT1718641E/pt unknown
- 2005-02-23 SI SI200530072T patent/SI1718641T1/sl unknown
- 2005-02-23 ES ES05719737T patent/ES2293552T3/es not_active Expired - Lifetime
- 2005-02-23 JP JP2005047294A patent/JP4256852B2/ja not_active Expired - Lifetime
- 2005-02-23 BR BR122012009489A patent/BR122012009489B8/pt active IP Right Grant
- 2005-02-23 DE DE602005002030T patent/DE602005002030T2/de active Active
- 2005-02-23 ME MEP-2007-448A patent/ME01643B/fr unknown
- 2005-02-23 BR BRPI0507984A patent/BRPI0507984B8/pt active IP Right Grant
- 2005-02-23 SI SI200531568T patent/SI2119715T1/sl unknown
- 2005-02-23 PL PL08075903T patent/PL2119715T3/pl unknown
- 2005-02-23 DE DE602005016162T patent/DE602005016162D1/de active Active
- 2005-02-23 CN CN2008101701465A patent/CN101381366B/zh not_active Expired - Lifetime
- 2005-02-23 TW TW094105364A patent/TWI336702B/zh active
2006
- 2006-08-16 IL IL177533A patent/IL177533A/en active IP Right Grant
- 2006-08-23 US US11/466,633 patent/US7572920B2/en not_active Expired - Lifetime
- 2006-08-30 ZA ZA2006/07241A patent/ZA200607241B/en unknown
- 2006-09-20 NO NO20064251A patent/NO332344B1/no active Protection Beyond IP Right Term
- 2006-09-22 MA MA29333A patent/MA28478B1/fr unknown
2007
- 2007-05-04 HK HK07104818A patent/HK1098472A1/xx unknown
- 2007-11-05 HR HR20070510T patent/HRP20070510T3/xx unknown
- 2007-11-14 CY CY20071101476T patent/CY1107008T1/el unknown
2008
- 2008-04-29 HK HK08104744.3A patent/HK1115118A1/xx unknown
- 2008-12-22 JP JP2008325152A patent/JP2009137974A/ja active Pending
2009
- 2009-06-30 US US12/458,092 patent/US7875637B2/en not_active Expired - Lifetime
- 2009-11-04 HR HR20090593T patent/HRP20090593T1/hr unknown
- 2009-11-12 CY CY20091101184T patent/CY1109610T1/el unknown
2012
- 2012-03-21 LU LU91962C patent/LU91962I2/fr unknown
- 2012-03-29 DE DE201212000018 patent/DE122012000018I1/de active Pending
- 2012-05-11 FR FR12C0034C patent/FR12C0034I2/fr active Active
- 2012-05-17 HU HUS1200008C patent/HUS1200008I1/hu unknown
- 2012-05-31 CY CY2012015C patent/CY2012015I1/el unknown
- 2012-05-31 CY CY2012016C patent/CY2012016I1/el unknown
- 2012-06-07 BE BE2012C025C patent/BE2012C025I2/fr unknown
- 2012-08-17 HR HRP20120667TT patent/HRP20120667T2/hr unknown
- 2012-08-29 CY CY20121100774T patent/CY1113084T1/el unknown
- 2012-11-09 NO NO2012017C patent/NO2012017I1/no not_active IP Right Cessation
2014
- 2014-01-27 AR ARP140100236A patent/AR094588A2/es not_active Application Discontinuation
2016
- 2016-03-15 NL NL300802C patent/NL300802I2/nl unknown

Also Published As

Publication number	Publication date
DE602005002030D1 (de)	2007-09-27
RU2501798C2 (ru)	2013-12-20
EP1857457A2 (fr)	2007-11-21
CY1109610T1 (el)	2014-08-13
EP1857457B1 (fr)	2009-08-19
JP2005272451A (ja)	2005-10-06
HRP20070510T3 (hr)	2007-12-31
DK1857457T3 (da)	2009-12-21
ES2293552T3 (es)	2008-03-16
KR20070020411A (ko)	2007-02-21
RU2369608C2 (ru)	2009-10-10
HRP20120667T1 (en)	2012-09-30
JP2009137974A (ja)	2009-06-25
ME01089B (me)	2013-03-20
MA28478B1 (fr)	2007-03-01
NO2012017I1 (no)	2012-11-26
ATE440095T1 (de)	2009-09-15
AU2005214271B2 (en)	2011-02-24
BR122012009489B1 (pt)	2019-02-19
BRPI0507984A (pt)	2007-07-24
CY1107008T1 (el)	2012-09-26
FR12C0034I1 (fr)	2012-06-15
HRP20090593T1 (hr)	2010-03-31
BR122012009489B8 (pt)	2023-03-21
IL177533A (en)	2010-12-30
CN101381366A (zh)	2009-03-11
CY2012015I2 (el)	2016-12-14
EP2119715B1 (fr)	2012-05-30
PT2119715E (pt)	2012-09-03
SI2119715T1 (sl)	2012-10-30
CN1946717A (zh)	2007-04-11
ATE370136T1 (de)	2007-09-15
NO20064251L (no)	2006-11-22
ME01643B (fr)	2010-05-07
NO2012017I2 (no)	2012-11-09
TW200530227A (en)	2005-09-16
HK1098472A1 (en)	2007-07-20
PL2119715T3 (pl)	2012-10-31
RS51137B (sr)	2010-10-31
SI1857457T1 (sl)	2010-01-29
DE122012000018I1 (de)	2012-06-06
EP1857457A3 (fr)	2007-12-05
BRPI0507984B1 (pt)	2018-07-03
AU2005214271B8 (en)	2011-03-03
CN101381366B (zh)	2011-06-15
CY2012016I2 (el)	2016-12-14
CY1113084T1 (el)	2016-04-13
ZA200607241B (en)	2008-04-30
HK1115118A1 (en)	2008-11-21
AU2005214271A1 (en)	2005-09-01
US7875637B2 (en)	2011-01-25
JP4256852B2 (ja)	2009-04-22
WO2005080384A9 (fr)	2006-11-30
HUS1200008I1 (hu)	2017-06-28
ES2331209T3 (es)	2009-12-23
NL300802I2 (fr)	2016-05-18
TWI336702B (en)	2011-02-01
CN100503605C (zh)	2009-06-24
KR101080029B1 (ko)	2011-11-04
SI1718641T1 (sl)	2007-12-31
US7157584B2 (en)	2007-01-02
CA2557538C (fr)	2010-08-17
AU2005214271A2 (en)	2005-09-01
NZ549755A (en)	2009-04-30
RS50537B (sr)	2010-05-07
PL1857457T3 (pl)	2009-12-31
ES2388945T3 (es)	2012-10-22
US20090270464A1 (en)	2009-10-29
US7572920B2 (en)	2009-08-11
DK1718641T3 (da)	2007-12-17
DE602005016162D1 (de)	2009-10-01
PL1718641T3 (pl)	2008-01-31
US20060281795A1 (en)	2006-12-14
AR047972A1 (es)	2006-03-15
IL177533A0 (en)	2006-12-10
HRP20120667T2 (hr)	2012-11-30
CY2012016I1 (el)	2016-12-14
MY142807A (en)	2011-01-14
AR094588A2 (es)	2015-08-12
EP1718641B1 (fr)	2007-08-15
CA2557538A1 (fr)	2005-09-01
DE602005002030T2 (de)	2008-05-08
US20050187269A1 (en)	2005-08-25
EP1718641A2 (fr)	2006-11-08
EP2119715A1 (fr)	2009-11-18
DK2119715T3 (da)	2012-09-10
BRPI0507984B8 (pt)	2023-03-21
BE2012C025I2 (fr)	2024-08-08
PT1857457E (pt)	2009-09-23
RU2006133898A (ru)	2008-03-27
CY2012015I1 (el)	2016-12-14
RU2009115498A (ru)	2010-10-27
WO2005080384A3 (fr)	2006-09-28
RS52376B (en)	2012-12-31
NO332344B1 (no)	2012-09-03
PT1718641E (pt)	2007-11-15
LU91962I2 (fr)	2012-05-21
WO2005080384A2 (fr)	2005-09-01

Publication	Publication Date	Title
FR12C0034I2 (fr)	2013-01-11	Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii
DK1720859T3 (da)	2010-04-26	Chemokinreceptorantagonister
EP2150115A4 (fr)	2011-08-03	Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
PL2513093T3 (pl)	2015-03-31	Nowi antagoniści receptora CCR2 i ich zastosowanie
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
BRPI0817245A2 (pt)	2015-06-16	Derivados e quinolina como antagonistas receptores de 5ht5a
EP1959959A4 (fr)	2011-09-21	Antagonistes de recepteur de prokineticine de morpholine-carboxamide
EP1641781A4 (fr)	2010-06-23	Antagonistes du recepteur cgrp de benzodiazepine
MA28359A1 (fr)	2006-12-01	Antagonistes du recepteur a l'hydroisoindoline tachykinine
DK2094709T3 (da)	2010-12-06	Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
EP1954268A4 (fr)	2010-11-03	Antagonistes du recepteur gcrp bicyclique du spirolactam
MA28815B1 (fr)	2007-08-01	Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
EP1951042A4 (fr)	2010-11-03	Antagonistes du recepteur cgrp du spirolactam
IL237513A0 (en)	2015-04-30	Piperazindiones as oxytocin receptor antagonists
EP1799672A4 (fr)	2011-01-19	Antagonistes du recepteur de cgrp
BRPI0820633A2 (pt)	2019-09-24	antagonistas de receptores de il-4 muteína modificada
EP1951228A4 (fr)	2010-11-03	Antagonistes du recepteur cgrp biclyclique de spirohydantoine
ATE414078T1 (de)	2008-11-15	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
EP2150248A4 (fr)	2011-06-29	Antagonistes de récepteur de glutamate et procédés d'utilisation
DE602005009355D1 (de)	2008-10-09	Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
IS8278A (is)	2006-01-31	Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
EP2067480A4 (fr)	2009-11-25	Récepteur de la muscline et son utilisation
EP1534736A4 (fr)	2006-11-02	Antagonistes de recepteur nogo
DE602005007719D1 (de)	2008-08-07	Antagonisten des opioidrezeptors